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Abstract: Since nearly 20% of breast-conserving surgeries (BCS) require re-operation, there 
is a clear need for developing new techniques to more accurately assess tumor resection 
margins intraoperatively. This study evaluates the diagnostic accuracy of a handheld terahertz 
pulsed imaging (TPI) system to discriminate benign from malignant breast tissue ex vivo. 
Forty six freshly excised breast cancer samples were scanned with a TPI handheld probe 
system, and histology was obtained for comparison. The image pixels on TPI were classified 
using (1) parameters in combination with support vector machine (SVM) and (2) Gaussian 
wavelet deconvolution in combination with Bayesian classification. The results were an 
accuracy, sensitivity, specificity of 75%, 86%, 66% for method 1, and 69%, 87%, 54% for 
method 2 respectively. This demonstrates the probe can discriminate invasive breast cancer 
from benign breast tissue with an encouraging degree of accuracy, warranting further study. 
© 2017 Optical Society of America 
OCIS codes: (110.6795) Terahertz imaging; (170.3880) Medical and biological imaging; (170.6935) Tissue 
characterization. 
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1. Introduction 
Breast cancer is by far the most common cancer among women worldwide [1]. A 
combination of an increased use of screening mammography, neoadjuvant chemotherapy and 
neoadjuvant endocrine therapy to downstage the size of the tumor, has significantly increased 
the number of patients suitable for breast-conserving surgery (BCS). Currently approximately 
two-thirds of newly diagnosed breast cancer patients in the United Kingdom and the United 
States undergo BCS as initial treatment [2, 3]. 
A key problem in BCS is that on average approximately 20% of patients require a re-
operation because of close or positive tumor margins on postoperative histopathological 
analysis [4, 5]. Re-operations potentially have a significant impact on patients and healthcare 
systems. They can result in an increased rate of surgical complications [6], compromise 
cosmetic outcome [7], delay adjuvant therapy, and increase anxiety and stress for patients and 
their families. Re-excision surgery also presents a high cost burden to healthcare systems; a 
recent study in the United States showed that the costs for a re-excision was $4721 per patient 
[8]. 
In an attempt to decrease the re-operation rate, techniques to intraoperatively assess tumor 
resection margins have been developed. Clinically established techniques include specimen 
radiography, intraoperative ultrasound, radiofrequency spectroscopy, frozen section analysis 
and touch imprint cytology. However, these all have limitations in terms of diagnostic 
accuracy, logistical or technical demands or cost-effectiveness [9]. Emerging techniques 
include Raman spectroscopy [10], diffuse reflectance spectroscopy [11–15], optical 
coherence tomography [16–18], mass spectroscopy [19, 20], bio-impedance spectroscopy 
[21], and (targeted) fluorescence imaging [22]. These techniques each have unique 
limitations, and their potential value for improving quality of care and reducing healthcare 
costs is yet unknown. 
Terahertz pulsed imaging (TPI) employs terahertz (THz) radiation (0.1 – 4 THz) for 
imaging biological tissue. Due to the millimetric penetration depth and sensitivity of THz 
radiation to changes in water content and tissue composition, and the submillimeter imaging 
resolution of TPI, this technique holds promise for imaging cancer [23]. Work performed to 
date has shown the ability of TPI to discriminate malignant from benign tissue in skin, colon, 
oral, gastric, brain and breast cancer [24]. In 2006, Fitzgerald et al. were the first to 
demonstrate the potential of TPI for identifying breast cancer during BCS [25]. They 
measured 22 freshly excised breast tissue samples, and demonstrated a good correlation 
between tumor size and shape assessed by TPI compared with histopathology. To better 
understand the origin of the observed contrast on TPI, Ashworth et al. used THz spectroscopy 
and showed that the absorption coefficient and refractive index of tumor were different to that 
of normal breast tissue in the THz region of the spectrum [26]. Following from their initial 
work, Fitzgerald et al. imaged 51 breast samples and assessed the diagnostic accuracy of TPI 
by using a range of THz image parameters and classification techniques [27]. They 
demonstrated an accuracy, sensitivity and specificity of 92%, 90% and 92%, respectively. 
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However, the TPI device used in their study is not suitable for intraoperative assessment of 
intact breast specimens due to the requirement for physical tissue disruption to obtain samples 
that fit the 20 x 20 mm sample holder. Importantly, the tissue samples included in their data 
set had a ‘homogeneous’ tissue composition, i.e. contained more than 50% of a single tissue 
type. This is not an accurate representation of the tissue composition found at the resection 
border of patients with close or positive margins, as involved margins are often identified 
microscopically as a small number of tumor cells immersed in a ‘background’ of fibrous 
and/or adipose tissue [28]. Thus, the diagnostic accuracy of TPI for detecting tumor close or 
at the margin remains underdetermined. 
 
Fig. 1. Schematic illustration of TPI handheld probe system. The emitted laser pulses are split 
into a “pump beam” and a “probe beam”. The pump beam is guided through the optical fibers 
in the umbilical cord, and subsequently incident on the photoconductive emitter to produce 
THz pulses. The probe beam is guided onto the photoconductive detector to detect the THz 
pulses reflected from the tissue sample. By altering the path length of the probe beam, the time 
of arrival at the detector in respect to the incident THz pulse can be changed, thus sampling the 
THz pulse in the time domain. 
 
Fig. 2. TPI handheld probe system. (A) Main unit with computer monitor, handheld imaging 
probe and black umbilical cord (visible on the right). (B) Close up of the handheld imaging 
probe. (C) Close up of the head of the imaging probe showing the black quartz window. The 
probe scans an area of 15 x 2 mm, and acquires data from 26 pixels (red). 
To facilitate the use of TPI to scan tumor resection margins intraoperatively, Teraview 
Ltd. (Cambridge, UK) has developed a handheld probe system. A single center study was 
performed to evaluate the ability of the TPI handheld probe to discriminate benign from 
malignant breast tissue in an ex vivo setting. The aims of the study were to obtain a data set 
that closely resembles the mixture of benign and tumor tissue commonly found at the 
resection border of patients with involved margins, and to evaluate the diagnostic 
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performance of the TPI handheld probe in terms of accuracy, sensitivity, specificity and 
predictive values using two data analysis and classification methods. 
2. Methods 
2.1 TPI handheld probe system 
The TPI handheld probe produces and detects THz pulses by guiding laser pulses from a 
femtosecond fiber laser (Menlo Systems GmbH, Martinsreid, Germany) down optical fibers 
to a photoconductive emitter and detector (Fig. 1). The 0.1 – 1.8 THz pulses are then guided 
by an oscillating mirror via a monolithic silicon section onto a quartz window present at the 
tip of the probe, scanning 26 pixels in an area of 15 x 2 mm at a frequency of 4 Hz (Fig. 2). 
During scanning each pixel acquires THz pulses over time to form a TPI image (Fig. 3). 
 
Fig. 3. Correlating TPI with histopathology. (A) Typical impulse function from breast tissue 
containing a high percentage of tumor, fibrous, and adipose cells, and air, respectively. Clear 
differences are seen between the impulse functions from air and from tissue, and between 
adipose and tumor/fibrous tissue, especially at time points t = 7.97 ps, t = 8.93 ps, and t = 9.67 
ps (black arrows). (B) TPI image from sample based on the amplitude of the impulse function 
at t = 7.97ps. A clear contrast can be seen at the air-tissue interface at pixel 5 and pixel 17. 
Note an ‘edge effect’ at these interfaces, causing a distortion in the impulse functions of these 
pixels. (C) Digital histopathology slide of the same tissue sample. By using the photograph of 
the sample in combination with the air-tissue interface visible in the TPI image, the TPI 15 x 2 
mm scan area can be accurately mapped onto the histopathology slide (black rectangle). The 
pixels are displayed as intermittent horizontal lines at 0.6 mm distance in the scan window. 
Pixel 5 – 17 contain invasive ductal/no special type (NST) carcinoma; the percentage of tumor 
cells in each of these pixel areas ranges between 5 – 10%. The tissue immediately surrounding 
the tumor cells (background) is composed of fibrous tissue, whilst fatty adipose tissue is seen 
inferiorly. 
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2.2 Data acquisition 
Between August 2013 and August 2014, following written, informed consent, breast tissue 
samples from patients who underwent BCS or mastectomy at Guy’s Hospital in London were 
scanned with the TPI probe (REC 12-EE-0493). Within 60 minutes post-excision, BCS or 
mastectomy specimens were inked and sliced by an Advanced Practitioner in the King’s 
Health Partners Cancer Biobank located adjacent to the operating theatre. Tissue samples 
were obtained for the study subject to the amount of tissue required for diagnostic purposes. 
Prior to scanning the samples, a Tegaderm layer (3M Tegaderm Film, 3M, Bracknell, UK) 
was applied to the probe’s quartz window, and the remainder of the probe was wrapped in a 
disposable protective sheath to prevent contamination from tissue. To enable consistent and 
controlled TPI measurements, tissue samples were placed in a standard histology cassette 
(Unisette, Simport, Beloeil, Canada) that tightly fitted the head of the probe (Fig. 4). All 
samples were scanned for 20 seconds. Upon completion of each measurement a photograph 
of the sample in the cassette was taken to facilitate accurate correlation of the TPI data with 
the final histology slide. 
 
Fig. 4. TPI measurement of tissue sample. (A) TPI handheld probe measurement of tissue 
sample positioned in histology cassette. Note that the head of the imaging probe tightly fits in 
the cassette, which facilitates applying a consistent pressure throughout the measurement, 
while preventing displacement of the probe. (B) Photograph of the tissue sample obtained after 
the sample was scanned. The imprint of the scan window on the sample is clearly visible. This 
photograph was used to facilitate accurate correlation of TPI data with histopathology. (C) 
Photograph of tissue sample after it was inked. Inking was performed to enable spatial 
orientation of the sample when analysed microscopically by the pathologist. 
After the sample was scanned, the Tegaderm layer was removed from the probe and a 60 
second air measurement was performed that was used as a reference for data processing. For 
orientation purposes the top and the right surface of the sample were inked red and black 
respectively, after which the histology cassette containing the sample was closed, placed in 
formalin for 24-48 hours, and subsequently processed and paraffin wax embedded. Three to 4 
micron sections were then cut and stained with hematoxylin and eosin. The histology slides 
were digitalized, and subsequently viewed and analyzed using histopathology slide viewer 
software (NDP.view2, Hamamatsu, UK). 
2.3 TPI data processing 
Each pixel of the TPI probe acquired raw THz pulses throughout the duration of the 
measurement. These pulses were deconvolved with the reference (“air without Tegaderm”) 
pulses and a double Gaussian filter was applied to reduce noise. All pulses were aligned in 
time to compensate for small offsets in the phase of the detected pulses due to changes in the 
optical path length that occur when optical fibers deform slightly with movement during 
scanning. The deconvolved pulses – called impulse functions - of each pixel were then 
averaged over time, resulting in 26 impulse functions, one for each of the 26 pixels to be used 
for discriminating benign from malignant breast tissue (Fig. 3(B)). 
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2.4 Correlation of TPI with histopathology 
By using the photograph depicting the imprint of the probe’s scan window on the sample, and 
the clear contrast from the air-tissue interface and tissue composition on the TPI image, the 15 
x 2 mm TPI scan area was mapped onto the digital histopathology image (Fig. 3(C)). To 
reduce potential inaccuracies in correlating TPI with histopathology, samples were excluded 
from further analysis if the number of tissue-containing pixels on TPI and histopathology 
differed by more than three. 
2.5 Histopathological analysis and selection of TPI data 
The digital histopathology slide of each sample was analyzed in the viewer software by a 
Consultant breast histopathologist (S.E.P.), and the percentage of different tissue types, 
namely tumor, fibrous, and adipose, were recorded in 5% intervals. For a subset of samples 
an intra-rater variability analysis was performed to assess the ability of the histopathologist to 
consistently score the tissue samples. For this analysis, a total of 92 pixels from 7 tumor 
samples and 125 pixels from 7 benign samples were re-evaluated in a blinded method by the 
same histopathologist 8 weeks after the first analysis. Weighted kappa coefficients were 
calculated to assess the agreement in subgroup classification between evaluation 1 and 2 
(kappa 2 function of the ‘irr’ package v0.84, R statistical software v3.2.2). A kappa 
coefficient (κ) greater than 0.80 was considered excellent agreement [29]. A Wilcoxon 
signed-rank test was performed to assess whether evaluation 1 was statistically significantly 
different from evaluation 2. The level of significance was defined as p < 0.05. 
Table 1. Pixel characteristics analysis data set. A total of 257 pixels were included in the 
TPI data set: 115 tumor pixels, 116 fibrous pixels and 26 pure adipose pixels. The tumor 
pixels predominantly consisted of invasive ductal/no special type carcinoma (N = 92) and 
invasive lobular carcinoma (N = 19). Most of the tumor pixels contained a low to 
moderate percentage of tumor cells ranging between 1 – 60% (N = 98). Almost all tumor 
cells had a background of pure fibrous tissue; only 5 had a background containing a mix 
of fibrous and adipose. Most of the fibrous pixels had a high percentage of fibrous cells 
ranging between 81 – 100% (N = 91). Only 26 of the 257 pixels consisted of pure adipose 
tissue. 
  Tumor  Fibrous  Adipose 
Tissue percentage 
groups (%) 
NST NST 
+ DCIS 
ILC Number 
pixels 
BG  Number 
pixels 
BG  Number 
pixels 
81 – 100  3 1  4 F  91 A  26a 
 
61 – 80  11 2  13 F  2 A 
 
  
41 – 60  22  6 28 F  7 A 
 
  
21 – 40  33 1 12 46 F: 43 
F/A: 3 
 
 3 A   
1 – 20   23  1 24 F: 22 
F/A: 2 
 13 A   
Number pixels 92 4 19 115   116   26 
NST = invasive ductal/no special type carcinoma; DCIS = ductal carcinoma in situ; ILC = invasive lobular 
carcinoma; BG = background tissue. In our dataset the background consisted of fibrous tissue (F), adipose tissue (A), 
or a mixture of fibrous and adipose tissue (F/A). 
aThese pixels contained 100% adipose tissue. 
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2.6 TPI data analysis and classification 
Classification of each of the selected impulse functions as malignant or benign was performed 
using two data analysis and classification methods: (1) heuristic parameters in combination 
with support vector machine (SVM) classification and (2) Gaussian wavelet deconvolution 
with Bayesian classification. 
The impulse function of each pixel is made of values at 301 time points, and given that 
information from both the time and frequency domain can be used to classify pixels, it was 
advantageous to reduce the dimensionality of the data for classification. In method 1 this was 
done by using parameters that described significant features in the impulse function or 
spectrum. Since a large number of time points or frequency points can be selected to form a 
parameter, a Receiver operator Characteristics (ROC) analysis was used to select the optimal 
characterizing parameters. The area under the ROC curve (AUROC) was used as an estimate 
of the classification ability of each parameter (illustrated in Fig. 5). AUROC analysis was 
performed on the data from 3 pathology groups; (i) the entire tumor and fibrous groups 
(excluding pure adipose), (ii) the tumor and 100% fibrous groups, and (iii) the tumor and 
100% adipose groups. From this analysis the top 11 parameters were selected to be used for 
classification of the data in the SVM (Table 2). To avoid effects of overfitting, the parameters 
chosen were tested to ensure they were not correlated, eliminating any parameters with an 
absolute correlation coefficient of 0.7 or more. The SVM function used for classification was 
from the Matlab native functions svmtrain.m and svmclassify.m using a radial basis function 
as the kernel to form the decision boundaries (MATLAB 2013A, The Mathworks Inc., 
Natick, MA, 2013). A grid search method was applied to optimize the sigma and box 
constraint terms as 0.3 and 1.1, respectively. 
 
Fig. 5. AUROC analysis to evaluate the discriminative power of the amplitude parameter for 
time indices 5.0 – 12.6 ps. The highest AUROC values of 0.72 and 0.70 were found at t = 9.42 
ps and t = 10.05 ps respectively, and these two parameters were therefore selected for tissue 
classification with SVM. 
Tissue classification was also performed using Gaussian wavelet deconvolution in 
combination with a Bayesian classifier. In contrast to heuristic parameters, Gaussian wavelet 
deconvolution can be applied to the full impulse function. This method was considered a 
suitable approach because of the similarities between the signal features of a Gaussian 
function and its derivatives, and the TPI impulse functions from breast tissue. Gaussian 
derivatives of order 0 (normal Gaussian function), 1, 2, 3 and 4 were applied to the impulse 
function of each pixel. Higher order Gaussian derivatives were not used to avoid potential 
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overfitting. The Gaussian deconvolved data were then fed into a Bayesian classification 
algorithm [30], and classified as tumor, fibrous or adipose, respectively. Pixels classified as 
adipose and fibrous were then grouped together as ‘benign’ in order to calculate the 
diagnostic performance of TPI. Similar to SVM, pixels were marked as tumor when 
containing any amount of cancer cells. 
The SVM and Bayesian classifier were trained individually using the leave-one-out 
method (LOO); leaving out the pixels of a single sample to be classified, and training each 
classifier on the other samples. The trained classifiers were then applied to the pixels of the 
sample that was left out. This process was repeated for all the samples, leaving each of them 
out in turn, and the results compiled to give accuracy, sensitivity, specificity, positive 
predictive value (PPV), and negative predictive value (NPV) for distinguishing malignant 
from benign tissue. 
3. Results 
3.1 Tissue sample characteristics and histopathology intra-rater reliability 
In total, 126 samples from 106 patients were scanned; 46 samples from 32 patients met the 
strict criteria established to ensure accurate correlation of TPI with histology, i.e. a 
photograph was available of the sample in the histology cassette, and the number of tissue 
containing pixels on TPI and histopathology differed by 3 or less. These samples were 
included for analysis. Of these, 20 samples contained tumor; 16 invasive ductal/no special 
type (NST) carcinoma, 2 NST admixed with DCIS, and 2 invasive lobular carcinoma (ILC). 
Twenty-two samples contained pure fibrous tissue or a mixture of fibrous and adipose tissue, 
and 4 samples contained pure adipose tissue. The total number of pixels for analysis was 257; 
the breakdown in terms of tissue composition is given in Table 1. 
The intra-rater reliability analysis showed excellent agreement in cell density subgroup 
classification between histopathological evaluation 1 and evaluation 2 (κ = 0.89) (p = NS). 
This confirmed that the established subgroups reliably reflected the tissue composition of the 
samples, and thus could be used to evaluate the performance of the TPI handheld probe 
system for different tissue groups. 
3.2 Heuristic parameters and SVM classification 
A total of 11 parameters were selected based on the AUROC analysis: 10 time domain 
parameters and 1 frequency parameter (Table 2) (Fig. 6). Most of the time domain parameters 
capture the area around the minimum amplitude of the pulse, and the return to baseline after 
the minimum. P1 – P7 were selected based on their overall ability of discriminating tumor 
from fibrous tissue with adipose, while P8 – P11 were specifically selected to enhance the 
TPI probe’s ability to discriminate tumor from pure fibrous tissue. All 11 parameters showed 
strong discriminative power to distinguish tumor from pure adipose tissue (mean AUROC = 
0.97, range 0.84 – 1.0). 
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 Fig. 6. Visualization of the selected parameters used in SVM classification. Each parameter is 
displayed in red. 
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Table 2. Overview of selected time domain and frequency domain parameters and their 
AUROC values. 
Parameter Definition AUROC value 
(cell density group)a 
P1 Quadratic fit 9.85 – 10.48 ps 0.76 (All T and F) 
P2 Linear fit 9.42 – 9.67 ps 0.73 (All T and F) 
P3 Amplitude at t = 9.42 ps 0.72 (All T and F) 
P4 Integral 9.14 – 9.65 ps 0.72 (All T and F) 
P5 Peak to peak (Emax minus Emin) 0.71 (All T and F) 
P6 Emin (minimum amplitude) 0.70 (All T and F) 
P7 Amplitude at t = 10.05 ps 0.70 (All T and F) 
P8 Quadratic fit 8.26 – 8.79 ps 0.74 (1 – 20% T, 100% F) 
P9 Integral 7.47 – 9.62 ps 0.83 (41 – 60% T, 100% F) 
P10 Emax (maximum amplitude) 0.73 (81 – 100% T, 100% F) 
P11 Power in spectrum at frequency = 1.11 THz 0.82 (61 – 80% T, 100% F) 
aT = tumor, F = pure fibrous tissue or a mixture of fibrous and adipose tissue, 100% F = pure fibrous tissue only 
 
The SVM classification results of the individual parameters, and the combination of 
parameters that performed best in terms of accuracy, may be found in Table 3. Overall, the 
combination of P1 and P6 provided the best performance with an accuracy, sensitivity, 
specificity, PPV and NPV of 75%, 86%, 66%, 67% and 85%, respectively. These values were 
obtained as a result of 16 of the 115 tumor pixels being misclassified as benign; 48 of the 142 
benign pixels were misclassified as tumor. All misclassified tumor pixels had a tumor content 
≤60%. Of the 48 misclassified benign pixels, 46 were fibrous pixels containing 81 – 100% 
fibrous cells; only 2 of the 1 – 80% fibrous pixels were misclassified as tumor, and all 26 pure 
adipose pixels were correctly identified as benign. The two-dimensional parametric plot of P1 
and P6 showed very little differences between tumor and high percentage fibrous tissue (Fig. 
7(A)); this provides an explanation for why most of the SVM classification errors occurred in 
these two tissue groups (Fig. 7(B)). Pixels with a high adipose content (1 – 80% fibrous pixels 
and pure adipose pixels) were generally clearly different from pixels containing a high 
percentage of fibrous tissue (81 – 100%) and cancer (Fig. 7(A)). The accuracy, sensitivity, 
specificity, PPV and NPV for discriminating 1 – 80% fibrous and pure adipose tissue from 
tumor (i.e. excluding the predominantly fibrous group with 81 – 100% purity) was 87%, 86%, 
96%, 98%, 75%, respectively. 
 
Fig. 7. Two-dimensional parametric plot (A) and SVM classification results (B) for the 
combination of parameters P1 and P6 that performed best in terms of accuracy. 
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3.3 Gaussian wavelet deconvolution and Bayesian classification 
The accuracy, sensitivity, specificity, PPV and NPV of Gaussian wavelet deconvolution and 
Bayesian classification was 69%, 87%, 54%, 60%, 84%, respectively (Table 3). Of the 115 
tumor pixels, 15 were misclassified as benign. All misclassified pixels contained ≤60% tumor 
cells. Sixty-six of the 142 benign pixels were wrongly classified as tumor; 64 of these were 
81 – 100% fibrous pixels, only two 1 – 80% fibrous pixels were misclassified. All pure 
adipose pixels were correctly classified. The accuracy, sensitivity, specificity, PPV and NPV 
of the handheld probe for discriminating 1 – 80% fibrous and pure adipose from tumor was 
88%, 87%, 96%, 98% and 77%, respectively. 
Table 3. Performance of heuristic parameters with SVM classification, and wavelet 
deconvolution with Bayesian classification. SVM classification results are shown for 
individual parameters and parameter combinations that performed best in terms of 
accuracy. The best individual parameter and parameter combination is underlined. 
Parameters Accuracy (%) Sensitivity (%) Specificity 
(%) 
PPVa 
(%) 
NPVb 
(%) 
P1 73 87 62 65 85 
P2 72 81 64 65 81 
P3 70 77 65 64 78 
P4 72 77 69 67 78 
P5 72 92 56 63 90 
P6 69 86 56 61 83 
P7 69 87 54 61 84 
P8 68 90 49 59 86 
P9 56 69 46 51 64 
P10 68 93 48 59 89 
P11 56 56 57 51 61 
P1 and P6 75 86 66 67 85 
P1, P6 and P11 71 72 70 66 76 
P1, P6, P9 and P11 67 56 75 65 68 
Gaussian wavelets 69 87 54 60 84 
aPPV = Positive predictive value 
  bNPV = Negative predictive value 
4. Discussion 
This study has evaluated the performance of a TPI handheld probe system to discriminate 
breast cancer from benign breast tissue in an ex vivo setting. A total of 257 pixels acquired 
from scanning 46 breast tissue samples were included for analysis. The tumor samples 
predominantly contained low-to-moderate tumor cell percentages, resembling the tissue 
composition found at the resection border of breast specimens from patients with positive 
margins after BCS. Two data analysis and classification methods were assessed: (1) heuristic 
parameters in combination with SVM classification and (2) Gaussian wavelet deconvolution 
with Bayesian classification. On the full data set the former provided the best performance in 
terms of accuracy (75%). Both methods had excellent sensitivity (86% and 87%, respectively) 
and thus show promise for identifying tumor cells close to or at the resection margins, 
allowing immediate further excision of appropriate margins and reducing subsequent second 
operations/re-excision rates if the TPI handheld probe had been used intraoperatively. 
Specificity however, was 66% and 54% for SVM and Bayesian respectively; for both 
methods the lower specificity was due to pixels with 81 – 100% fibrous tissue that were 
wrongly classified as tumor. The accuracy, sensitivity and specificity increased to 88%, 87%, 
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and 96% respectively after excluding the 81 – 100% fibrous tissue from the classification 
results. 
The reported pooled sensitivity and specificity of the established techniques to 
intraoperatively assess tumor margins during BCS are 53% (95% CI 45 – 61%) and 84% 
(95% CI 77 – 89%) for specimen radiography, 59% (95% CI 36 – 79%) and 81% (95% CI 66 
– 91%) for ultrasound imaging, 71% and 68% for radiofrequency spectroscopy, 86% (95% CI 
78 – 91%) and 96% (95% CI 92 – 98%) for frozen section analysis, and 91% (95% IC 71 – 
97%) and 95% (95% IC 90 – 98%) for imprint cytology, respectively [9]. Thus, based on the 
results of the present study, the TPI handheld probe appears to perform similarly or better in 
terms of sensitivity, while the performance in terms of specificity is lower. Compared to 
specimen radiography and ultrasound, which are also imaging technologies, TPI has the 
potential advantage that image interpretation is not needed as the device can provide a binary 
read-out (tumor or no tumor). This may overcome the need for the training required for 
obtaining ultrasound accreditation [31]. Potential advantages over the histopathological 
techniques frozen section analysis and imprint cytology are the fact that TPI is non-invasive 
(i.e. physical tissue disruption is not required), it does not require an on-site cytologist or 
histopathologist, and allows for assessing a larger tissue surface. 
Results published to date on the diagnostic performance of emerging techniques for 
margin assessment have shown a sensitivity and specificity of 92% (95% CI 86 – 96%) and 
97% (95% CI 93 – 98%) for Raman spectroscopy [10], 67 – 85% and 67 – 96% for diffuse 
reflectance spectroscopy [11–15], 60 – 100% and 69 – 92% for optical coherence tomography 
[16–18], 93 – 100% and 91.9 – 100% for mass spectroscopy [19, 20], and 87% and 76% for 
bioimpedance spectroscopy [21], respectively. Although the performance of the handheld 
probe in this study is somewhat lower than some of the other emerging techniques, TPI uses a 
different region of the electromagnetic spectrum and thus provides complementary 
information. It is possible that combinations of technologies could significantly improve the 
overall accuracy of identifying involved margins. 
Several papers have reported on the ability of TPI to discriminate freshly excised benign 
from malignant breast tissue [25, 27, 32, 33]. Ashworth et al. performed a small pilot study 
using a prototype version of the TPI handheld system [32]; all other studies were conducted 
with systems not suited for intraoperative imaging of WLE specimens. Similar to the present 
results, Ashworth et al. found that THz impulse functions from fibrous tissue and breast 
cancer had strong similarities, while impulse functions from adipose tissue had clearly 
different features. However, none of the TPI studies in breast cancer published to date have 
used a data set representative of the tissue composition found at the resection border of 
patients with positive margins, as all tumor samples included for analysis contained >50% 
tumor cells. Thus, the results in our study are the first that can be used to derive insight in the 
potential benefits of TPI in enabling more accurate and complete tumor resection in BCS. 
The accuracy, sensitivity and specificity of the TPI probe for discriminating tumor from 
mixed fibrous and adipose tissue, and pure adipose tissue, was 87%, 86%, and 96% for SVM, 
and 88%, 87% and 96% for Bayesian, respectively. Discrimination of these tissue types is 
most relevant clinically, as the incidence of breast cancer is higher in older women, who are 
likely to have fatty or mixed fibrous and fatty breasts compared to younger women who may 
have more dense breasts primarily composed of fibrous tissue [34]. 
While the results of this feasibility study are promising, two limitations were noted. 
Firstly, the 0.6 mm pixel distance used for correlating TPI and histopathology was based on a 
linear movement of the THz pulse beam across the 15 x 2 mm scan area. However, in practice 
the THz beam moves faster in the center of the scan window and slows down upon reaching 
the top and bottom boundary, resulting in a larger distance between pixels located in the 
center compared to the edges. This introduces a degree of inaccuracy, which was not 
accounted for in this study. Secondly, the current data set does not contain THz pulses from 
cases of pure DCIS. These samples could not be assessed, as DCIS is generally non-palpable 
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and particularly problematic to sample in the fresh state without impairment of gold-standard 
histological assessment. However, since DCIS is often the cause of the clinical 
recommendation for re-operations in BCS, it is of key importance to assess the sensitivity of 
the TPI handheld probe for detecting DCIS. Based on the results of this feasibility study, a 
study will be performed in which TPI data will be acquired on tissue specimens with DCIS, to 
determine the ability of TPI to accurately detect DCIS. 
In conclusion, the results of this study show that the TPI handheld probe can discriminate 
invasive breast cancer from benign breast tissue with a high sensitivity and an encouraging 
degree of accuracy. The main challenge for TPI is accurate discrimination of cancer from 
tissue containing a high percentage of fibrous stroma due to the similarities in the THz pulse 
between these two types of tissue. Larger studies are warranted to assess the performance of 
this technique on different tumor types including DCIS, and its impact on re-operation rate. 
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